Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10325232 | 0.94 | ASGR1 (0.33) | CA14SSTR4DPP4ASGR1NFKB1 | |
| SCHEMBL2660690 | 0.94 | CA14 (0.33) | CA14SSTR4DPP4ASGR1NFKB1 | |
| SCHEMBL1238808 | 0.94 | CA14 (0.33) | CA14SSTR4DPP4ASGR1NFKB1 | |
| SCHEMBL13641157 | 0.94 | ASGR1 (0.33) | CA14SSTR4DPP4ASGR1NFKB1 | |
| SCHEMBL10323856 | 0.93 | CA14 (0.34) | CA14SSTR4DPP4ASGR1NFKB1 | |
| SCHEMBL1067463 | 0.92 | EPHX1 (0.36) | CA14DPP4HSD11B1L3MBTL1 | |
| SCHEMBL4914499 | 0.90 | CA14 (0.37) | CA14SSTR4DPP4ASGR1NFKB1 | |
| SCHEMBL20674336 | 0.89 | SLC6A4 (0.35) | CA14RENCHRM3 | |
| SCHEMBL4711748 | 0.88 | CA14 (0.39) | CA14DPP4ASGR1NFKB1NFKB2 | |
| SCHEMBL8218482 | 0.88 | NFKB1 (0.34) | CA14SSTR4ASGR1NFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240252506-A1 | COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2024-08-01 | — | — | US | disclosed |
| EP-4405353-A1 | NEW COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | F. Hoffmann-La Roche AG (CH) | 2024-07-31 | — | — | EP | disclosed |
| EP-4126855-B1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN LA ROCHE (CH) | 2024-04-24 | — | — | EP | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230167127-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-06-01 | — | — | US | disclosed |
| WO-2023041757-A1 | NEW COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2023-03-23 | — | — | WO | disclosed |
| EP-4126855-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | F. Hoffmann-La Roche AG (CH) | 2023-02-08 | — | — | EP | disclosed |
| CN-115298176-A | Compounds and their use in the treatment of bacterial infections | 豪夫迈·罗氏有限公司 | 2022-11-04 | — | — | CN | disclosed |
| WO-2021190727-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2021-09-30 | — | — | WO | disclosed |
| EP-2831075-A1 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS | Cubist Pharmaceuticals, Inc. (US) | 2015-02-04 | — | — | EP | disclosed |
| WO-2013149121-A1 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS | CUBIST PHARMACEUTICALS, INC. (US) | 2013-10-03 | — | — | WO | disclosed |
| CN-100463908-C | Substituted 8 '-pyridyl-dihydrospiro- [ cycloalkyl ] -pyrimido [1, 2-a ] pyrimidin-6-one and 8' -pyrimidinyl-dihydrospiro- [ cycloalkyl ] -pyrimido [1, 2-a ] pyrimidin-6-one derivatives | SANOFI AVENTIS (FR) | 2009-02-25 | — | — | CN | disclosed |
| CN-1777607-A | Substituted 8 '-pyridyl-dihydrospiro- [ cycloalkyl ] -pyrimido [1, 2-a ] pyrimidin-6-one and 8' -pyrimidinyl-dihydrospiro- [ cycloalkyl ] -pyrimido [1, 2-a ] pyrimidin-6-one derivatives | SANOFI AVENTIS (FR) | 2006-05-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | CA14 3425/4885SSTR4 710/4885DPP4 332/4885 |
| US-20230167127-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | LTB4R, C5, C3AR1 | CA14 2607/4885SSTR4 1973/4885DPP4 1404/4885 |
| US-20240252506-A1 | COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTION | C3AR1, LTB4R, C5 | CA14 2865/4885SSTR4 2569/4885DPP4 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.